目的 研究复方芩兰口服液与银黄口服液治疗新型冠状病毒感染的临床疗效。方法 选取2022年11月—2023年1月天津市第三中心医院收治的轻中度新型冠状病毒感染患者280例为研究对象，根据用药差别将患者分为银黄组（145例）和复方芩兰组（135例）。两组患者在38.5 ℃以下单用复方芩兰口服液或银黄口服液进行清热治疗。复方芩兰组患者口服复方芩兰口服液，10～20 mL/次，3次/d；银黄组口服银黄口服液组，10～20 mL/次，3次/d。两组均治疗7 d。观察两组的临床疗效，比较两组咽痛、声音嘶哑、咽部干、发热的缓解情况，同时比较两组治疗前后白细胞介素-6（IL-6）和肿瘤坏死因子-α（TNF-α）的变化情况。结果 治疗后，复方芩兰组总有效率是98.52%，显著高于银黄组的90.34%（P＜0.05）。治疗后，复方芩兰组咽痛和发热的总有效率分别是98.51%、97.78%，显著高于银黄组的89.66%、88.97%（P＜0.05），两组声音嘶哑和咽部干燥的总有效率差异无统计学意义。治疗后，两组患者血清IL-6、TNF-α水平均较治疗前显著降低（P＜0.05），且治疗后，复方芩兰组TNF-α、IL-6水平低于银黄组（P＜0.05）。结论 复方芩兰口服液治疗轻型和中型新型冠状病毒感染患者具有较好的临床疗效，可明显改善患者咽痛和发热症状，降低TNF-α和IL-6水平。

Objective To study the clinical effect of Compound Qinlan Oral Liquid and Yinhuang Oral Liquid in treatment of novel coronavirus infection. Methods A total of 280 patients with mild to moderate novel coronavirus infection admitted to the Third Central Hospital of Tianjin from November 2022 to January 2023 were selected as the study objects. According to the differences in drug use, the patients were divided into Yinhuang group (145 cases) and Compound Qinlan group (135 cases). Two groups of patients were treated with Compound Qinlan Oral Liquid or Yinhuang Oral Liquid to clear heat under 38.5 ℃. Patients in the Compound Qinlan group were po administered with Compound Qinlan Oral Liquid, 10 — 20 mL/time, 3 times daily. Patients in the Yinhuang group were po administered with Yinhuang Oral Liquid, 10 — 20 mL/time, 3 times daily. Both groups were treated for 7 d. The clinical efficacy of two groups was observed, and the relief of pharyngeal pain, hoarseness, dryness of pharynx and fever between the two groups were compared. The changes of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) before and after treatment were also compared between the two groups. Results After treatment, the total effective rate of Compound Qinlan group was 98.52%, which was significantly higher than that of Yinhuang group (90.34%) (P < 0.05). After treatment, the total effective rates of pharyngeal pain and fever in Compound Qinlan group were 98.51% and 97.78%, respectively, which were significantly higher than 89.66% and 88.97% in Yinhuang group (P < 0.05). There was no statistical significance in the total effective rates of hoarseness and dryness of pharynx between the two groups. After treatment, serum levels of IL-6 and TNF-α in two groups were significantly decreased compared with before treatment (P < 0.05), and after treatment, the levels of TNF-α and TNF-6 in Compound Qinlan group were lower than those in Yinhuang group (P < 0.05). Conclusion Compound Qinlan Oral Liquid has good clinical efficacy in treatment of mild and medium novel coronavirus infection patients, and can significantly improve the symptoms of pharyngeal pain and fever, and reduce the levels of TNF-α and IL-6.

R974